KÇKısmet Çıkı

Kısmet Çıkı

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kısmet Çıkı has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MOLİBDEN KOFAKTÖR EKSİKLİĞİ-TEK MERKEZ DENEYİMİ

    by Ayşen Koçyiğit, Buğse Tıraş, Ayşe Şenol Ersak, Kısmet Çıkı, Yılmaz Yıldız, Ali Dursun, Serap Sivri

    Amaç: Molibden kofaktör eksikliği (MoKE), molibden-bağımlı enzimlerin işlev kaybı ile karakterize, nadir görülen, ağır seyirli otozomal resesif geçişli bir metabolik hastalıktır. Bu çalışmada bölümümüzde takip edilen MoKE olgularının klinik, biyokimyasal, radyolojik ve genetik özelliklerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Hacettepe Üniversitesi Çocuk Metabolizma Bilim Dalında 2009-2025 yılları arasında MoKE tanısı alan 10 hastanın dosyaları geriye dönük olarak incelendi. Bulgular: Hastaların demografik özellikleri, klinik bulguları, laboratuvar sonuçları, görüntüleme ve EEG bulguları ile genetik analizleri değerlendirildi. Olguların 8’i erkekti (n=8) ve 9’unda (n=9) ebeveynler arasında akrabalık vardı. Sekiz hasta erken, iki hasta geç başlangıçlı MoKE grubundaydı. Erken başlangıçlı olgularda nöbetler en sık bulgu iken geç başlangıçlı olgular enfeksiyon sonrası gelişen motor kayıp ile başvurmuş ve nöbet izlenmemiştir. Laboratuvar incelemelerinde tüm hastalarda ürik asit düzeyi düşük olup 0-2 mg/dL aralığındaydı ve idrar sülfit düzeyleri değişkendi. Kraniyal görüntülemede tüm olgularda kistik ensefalomalazi saptanmıştır. Genetik analiz yapılan 7 hastadan 3’ünde MOCS1, 4’ünde MOCS2 varyantı gösterilmiştir. İzlemde 7 hasta kaybedilmiş olup kaybedilme yaşları 6-103 ay arasındaydı. Kaybedilen 7 hastanın 6’sı erken başlangıçlı MoKE grubundaydı. 3 hasta yaşamını sürdürmektedir. Ortalama yaşam süresi 73,4 aydır.Sonuç: MoKE yenidoğan döneminde başlayan inatçı nöbet ve düşük ürik asit düzeyi varlığında ayırıcı tanıda ön planda düşünülmelidir. Yenidoğan dönemi dışında da klinik bulguların görülebileceği unutulmamalıdır.

  • Hypertrophic cardiomyopathy as a novel phenotypic feature of NSUN3 -related mitochondrial disease: a case report with review of the literature

    by Ayşe Şenol Ersak, Tuğçe Çağıran, Ayşen Koçyiğit, Kısmet Çıkı, Yılmaz Yıldız, Ebru Aypar, Serap Ketenci İşLek, Pelin Özlem Şimşek Kiper, Göknur Haliloğlu, Ali Dursun

    Objectives: NSUN3 encodes a mitochondrial RNA methyltransferase responsible for cytosine methylation at the tRNA wobble base, which plays a role in the regulation of mitochondrial translation. Variants in NSUN3 lead to impaired oxidative phosphorylation resulting in multisystem involvement. Reported cases to date have described developmental delay, hypotonia, optic atrophy and neurological involvement. Cardiac manifestations, however, have not yet been clearly associated with NSUN3 deficiency. Here, we report hypertrophic cardiomyopathy (HCM) as a new clinical feature and the long-term follow-up of our case, further expanding the phenotype of NSUN3 -related disease. Case presentation: An 18-year-old girl was referred for visual loss, progressive fatigue, muscle weakness and HCM. Initial symptoms started as hypotonia in infancy and proceeded with developmental delay, reduced visual acuity and chest pain. At the age 15 years, she was diagnosed with HCM. Cardiac magnetic resonance imaging showed concentric left ventricular (LV) hypertrophy with septal thickness measuring up to 20 mm, LV ejection fraction was preserved (70 %). Whole exome sequencing identified a homozygous likely pathogenic variant in the NSUN3 gene: NM_022072.5: c.465dup (p.Gly156ArgfsTer6), for which both parents were found to be heterozygous carriers. Conclusions: To our knowledge, this is the first reported case of NSUN3 -related mitochondrial disease with HCM. An increasing number of reported cases will likely contribute to a more comprehensive understanding of the clinical phenotype and genotype–phenotype correlations.

  • Glutathione synthetase deficiency: severe hemolysis and metabolic acidosis with symptoms in the intrauterine period

    by Aysegul Demirsu, Ferid Aliyev, Elif Yucel, Kısmet Çıkı, Yılmaz Yıldız, Gizem Ürel-Demir, Pelin Ozlem Simsek-Kiper, Ali Dinc Bozat, Hakan Aykan, Ibrahim Halil Öncel, et al.

    Objectives: Glutathione synthetase deficiency (GSSD) is a rare, autosomal recessive disease that causes disruption in glutathione metabolism. According to clinical findings, it occurs in three forms: mild, moderate and severe. In severe forms, metabolic acidosis and hemolytic anemia are accompanied by neurological findings. Although there is no definitive treatment, early initiation of sodium bicarbonate, vitamin C, and vitamin E supplements is one of the most important factors affecting prognosis. Case presentation: Here we present a severe case of GSSD in a neonate with intrauterine periventricular cystic lesions, and postnatally developed severe hemolytic anemia, metabolic acidosis, and dilated cardiomyopathy. Exchange transfusion and peritoneal dialysis were performed because of refractory hyperbilirubinemia and acidosis despite sodium bicarbonate and vitamin supplementation. Conclusions: Early diagnosis and initiation of supportvive treatment with sodium bicarbonate, vitamin C, and vitamin E are esential for survival in severe GSSD. Dilated cardiomyopathy may represent a new complication of disease, highlighting the need for early cardiac monitoring.

  • Open Access

    The effect of triheptanoin treatment on clinical and laboratory outcomes in patients with long-chain fatty acid oxidation disorder

    by Engin Köse, Aslı İnci, Havva Yazıcı, Tanyel Zübarioğlu, Sebile Kılavuz, Kısmet Çıkı, Esra Er, Mehmet Cihan Balcı, Ayça Burcu Kahraman, Neslihan Önenli Mungan, et al.

    Long-chain fatty acid oxidation disorders (LC-FAOD) are a rare metabolic condition that results in impaired fatty acid utilization, leading to metabolic crises, hospitalization, and reduced quality of life. Despite dietary management, many patients experience ongoing complications. Triheptanoin, a seven-carbon triglyceride, has emerged as a therapeutic alternative by providing an energy source and supporting metabolic stability. This study aims to evaluate the clinical outcomes of LC-FAOD patients receiving triheptanoin therapy in Türkiye. A retrospective nationwide study was conducted to analyze 14 patients with LC-FAOD who received oral triheptanoin as part of a compassionate use program in Türkiye. The study collected data on emergency department visits, hospitalizations, metabolic decompensation episodes, creatine kinase (CK) levels, hypoglycemia, and cardiac function. Additionally, patient-reported outcomes were assessed through surveys. The findings of the study demonstrated that triheptanoin treatment led to a significant reduction in the number of emergency service applications and hospitalizations per month (p < 0.01). A notable decrease in the frequency of myalgia attacks was observed, while the decline in rhabdomyolysis episodes did not reach statistical significance. Furthermore, creatine kinase levels during metabolic crises exhibited a substantial decrease following triheptanoin therapy (p < 0.0001).Among patients with cardiomyopathy, cardiac function showed improvement in four out of seven patients. Survey data indicated an improvement in appetite, physical performance, and overall quality of life. Conclusion: Triheptanoin treatment has been demonstrated to be associated with significant clinical improvements in patients diagnosed with LC-FAOD, including a reduction in the frequency of emergency department visits, hospitalizations, and metabolic crises. These findings provide support for the utilization of triheptanoin as a therapeutic approach that holds promise in the management of LC-FAOD. What is Known: • Long-chain fatty acid oxidation disorders (LC-FAOD) are associated with significant morbidity due to metabolic crises, despite conventional dietary treatment including medium-chain triglycerides (MCT). What is New: • This nationwide study demonstrates that triheptanoin therapy significantly reduces emergency visits, hospitalizations, and creatine kinase levels during crises, and improves patient-reported outcomes, including physical activity and quality of life, in LC-FAOD patients in Türkiye.


  • Open Access

    Comprehensive analysis of 1103 infants referred to a single center due to positive newborn screening test for phenylketonuria

    by Ayça Burcu Kahraman, Kısmet Çıkı, Begüm Poşul, Mustafa Güvercin, Yılmaz Yıldız, Ali Dursun, Serap Sivri, Turgay Coşkun, Ayşegül Tokatlı

    Objective. Phenylketonuria (PKU) is a prevalent inherited metabolic disorder, resulting from biallelic pathogenic variants in the PAH gene. This study aimed to assess the clinical characteristics of 1103 infants referred to a single center due to positive newborn screening (NBS) tests for PKU, providing insights into screening and diagnosis. Methods. The health records of infants who were referred with suspicion of PKU through the Turkish national NBS program to a single referral center between January 2016 and January 2023 were retrospectively reviewed. The study analyzed demographic data, clinical findings, and diagnostic results from hospital records. Logistic regression analysis identified significant predictors of age at admission. Results. This study highlights significant regional differences within Türkiye regarding DBS collection, result reporting, and age at admission. Significant delays in age at admission (expressed as median, [Q1-Q3]) were noted in the Eastern Anatolia (34 days [27-42]), Southeastern Anatolia [34 days (25-42)], and Black Sea regions [26 days (19-33)]. Out of the referred infants, 5.1% and 2.4% had transient tyrosinemia and transient hyperphenylalaninemia, respectively, and these transient conditions were more prevalent among neonates with a history of jaundice. Phenylalanine level was normal in 38.1% of the patients and was considered false positive. Among the 26 (2.36%) patients admitted after 90 days (late admissions), there were 2 PKU patients with untreated Phe levels >20 mg/dL (n=2). Among the 140 infants requiring treatment, 1.43% (n=2) were late admissions (>90 days). A history of PKU in the family and higher initial Phe levels were associated with earlier admissions. Conclusion. This comprehensive analysis underscores the need to enhance NBS programs, particularly in regions with identified delays. Improving healthcare infrastructure, increasing awareness, and implementing targeted health policies are crucial for timely diagnosis and treatment. Future research should address regional disparities and optimize screening protocols to improve outcomes for affected infants.


  • Open Access

    Impact of the COVID-19 Era on Phenylalanine Levels and Classical Phenylketonuria Patients Follow-Up: A Retrospective Analysis

    by Ayca Burcu Kahraman, Yılmaz Yıldız, Neslihan Nisa Geçici, Kısmet Çıkı, İzZet Erdal, Halil Tuna Akar, Ali Dursun, Ayşegül Tokatli, Serap Sivri

    Objective: Phenylketonuria is a metabolic disorder resulting from mutations in the PAH gene, causing elevated blood phenylalanine (Phe) levels which can lead to severe neurological damage if untreated. The primary treatment is a lifelong low-protein diet with amino acid substitutes and micronutrient supplements. During the COVID-19 pandemic, classical phenylketonuria (PKU) patients faced significant challenges, including restricted access to routine care like clinical visits and metabolic control monitoring. The aim of the this study was to examine the disruptions in outpatient visits, the variances in pre- and post-pandemic Phe levels, and clinical severity among patients who contracted COVID-19. Material and Methods: Starting from the pandemic date of March 11, 2020, demographic data, laboratory characteristics, and details about COVID-19 infection were retrospectively reviewed for classical PKU patients with accessible electronic records from March 2018 to March 2022. Results: When the median blood Phe levels before and after the pandemic were compared, a significant difference was found. We observed that adult patients diagnosed with classical PKU often defaulted on their follow-up appointments. Conclusion: The COVID-19 pandemic significantly disrupted the follow-up and management of classical PKU patients. However, no severe COVID-19 cases were reported among this population, suggesting they did not face an increased risk from the infection. This study emphasizes the critical need to develop robust strategies for patient engagement and follow-up, especially for adult classical PKU patients who are at risk of discontinuing routine care.

  • Clinical and laboratory characteristics of propionic acidemia in a Turkish cohort

    by Halil Tuna Akar, Ayça Burcu Kahraman, Yılmaz Yıldız, Berat Baran, Kısmet Çıkı, Turgay Coşkun, Didem Yücel Yılmaz, Rıza Köksal Özgül, Hayrettin Hakan Aykan, Ali Dursun, et al.

    Objectives: Propionic acidemia (PA) is an autosomal recessive multisystem disorder caused by the deficiency of propionyl-CoA carboxylase, encoded by PCCA and PCCB genes. This retrospective study presents the clinical and laboratory characteristics of PA patients followed up in our center. Methods: Included in the study were 50 patients diagnosed in a single center with propionic acidemia between 1984 and 2020, whose electronic and written hospital records regarding demographic, clinical, and laboratory features, along with diagnostic and therapeutic approaches, were reviewed retrospectively. Results: This cohort had a median age at diagnosis of 18 days and 91.1 % (n=41) were born at term. Consanguinity was notably prevalent (91.1 %), and a family history of PA was reported in 14 % of cases. No significant relationships were observed between clinical and laboratory parameters and mortality. Laboratory findings at the time of diagnosis revealed significant metabolic abnormalities, including low levels of free carnitine, elevated C3 propionyl carnitine, and varied amino acid imbalances. Twenty-three patients exhibited developmental delay and/or intellectual disability. Brain magnetic resonance imaging unveiled white matter involvement and ventricular dilatation in 9/25 patients. Furthermore, dilated cardiomyopathy (26 %) was noted in patients who had cardiac assessments. Among the study cohort, 27 patients survived, 23 patients died during follow-up. No significant relationships were observed between clinical and laboratory parameters and mortality. Conclusions: Despite improvements in the understanding of the pathophysiology and advances in diagnostic and treatment approaches, propionic acidemia and its long-term complications can still lead to severe consequences. This comprehensive evaluation offers valuable insights into the multifaceted nature of PA.


  • High prevalence of low bone mineral density in young adults with phenylketonuria

    by Kısmet Çıkı, Ayça Burcu Kahraman, Halil Tuna Akar, Yılmaz Yıldız, Ali Dursun, Ayşegül Tokatlı, Turgay Coşkun, Serap Sivri

    Background: It has been reported that phenylalanine (Phe)-restricted diets may have negative effects on bone health in patients with classical phenylketonuria (cPKU). We aimed to evaluate bone mineral density (BMD) in adults with cPKU and determine the risk factors associated with low BMD. Methods: Eighty adult patients with cPKU were examined, including 41 women and 39 men. The age range was 18.3-39.4 years (median 22.8). The femoral and lumbar BMD were measured by dual energy X-ray absorptiometry. The patients were evaluated in two groups with low (Z-score <=-2) and normal BMD (Z-score > -2). Results: Low BMD was detected in 20 patients (25%). The low BMD group had significantly more males (75% vs 40%, p < 0.01) and lower mean body mass index (BMI, 22.4 vs 24.5 kg/m2, p = 0.02). Paradoxically, mean blood calcium and 25-hydroxy vitamin D levels were higher in the low BMD group, but only marginally (10.0 vs 9.8 mg/dl and 25.1 vs 21.0 g/L respectively, p < 0.05). The groups did not differ significantly with regards to age, mean Phe levels at diagnosis, median Phe levels above the age of 12 years, other nutritional parameters or vitamin-mineral supplementation. There was no history of clinical fractures. Discussion: Although osteopenia, osteoporosis and low BMD have been reported in PKU, conflicting data also exist. Our study of a large adult cPKU cohort strongly supports previously published limited data that suggest male sex and low BMI confer a higher risk for low BMD in cPKU; and age, Phe levels and dietary adherence do not. In our study, although the patients were young, low BMD was quite common (25%). Bone health should be evaluated even in young adults with cPKU, especially in males and those with low BMI, regardless of treatment compliance and vitamin-mineral status. Prospective studies reporting on clinical outcomes such as bone pain or fractures will be valuable in the coming years.


  • Open Access

    Comprehensive analysis of genotypic and phenotypic characteristics of biotinidase deficiency patients in the eastern region of Türkiye

    by Kısmet Çıkı, Ceren Alavanda, Emine İpEk Ceylan, Tijen Tanyalçın, Sebile Kılavuz

    Background. Biotin is a water-soluble vitamin that plays a key role in carboxylation. The formation of free biotin is impaired in biotinidase deficiency (BD), resulting in impaired biotin-dependent carboxylase functions. Based on the percentage of residual serum enzyme activity, BD is classified as partial and profound. Methods. Retrospective data including gender, age, parental consanguinity, family history, biotinidase activity analyses, type of deficiency (partial-profound), physical examination, treatment, and genotypes were evaluated in patients diagnosed with biotinidase deficiency in a single center in the eastern region of Türkiye. Patients whose biotinidase enzyme activity was below 30% with biallelic variants in the BTD gene were diagnosed as BD. Results. A total of 302 patients were included in the study. Parental consanguinity was present in 135 (44.7%) of them. Two hundred eighty-six (94.7%) were diagnosed by neonatal screening, 14 (4.6%) by family screening and two (0.06%) by clinical symptoms. Ninety-two (30.5%) of the patients were followed-up with profound deficiency and 210 (69.5%) with partial deficiency. A total of 306 variants were detected. Twenty different variants (3 novel - 3 rare) and 31 different genotypes were detected. The 3 most frequently detected variants were c.410G>A (p.Arg137His; 47.3%), c.1270G>C (p.Asp424His; 29.7%), and c.38_44delGCGGCTGinsTCC (p.Cys13Phefs*36; 15.3%). The 3 most frequently identified genotypes were c.410G>A (p.Arg137His) / c.1270G>C (p.Asp424His) compound heterozygous (32.4%), c.410G>A (p.Arg137His) homozygous (24.8%), and c.38_44delGCGGCTGinsTCC (p.Cys13Phefs*36) / c.1270G>C (p.Asp424His) compound heterozygous (12.2%). Patients with c.410G>A (p.Arg137His) homozygous variant, c.38_44delGCGGCTGinsTCC (p.Cys13Phefs*36) homozygous variant and c.38_44delGCGGCTGinsTCC (p.Cys13Phefs*36) / c.410G>A (p.Arg137His) compound heterozygous variant were statistically significantly associated with profound deficiency. Compound heterozygosity of c.410G>A (p.Arg137His) / c.1270G>C (p.Asp424His) variants were significantly associated with partial deficiency. Conclusions. The association between the BTD genotype and biochemical phenotype is not always consistent. Our study provides valuable data by adding variants with genotype-phenotype correlations to the literature and three novel variants, which can provide significant guidance in clinical follow-up.


  • Dysmorphic Findings in SAHH Deficiency with a Novel Variant in the AHCY Gene

    by Kismet Ciki, Ceren Alavanda

    Introduction: S-adenosylhomocysteine hydrolase (SAHH) is one of the enzymes involved in converting methionine to homocysteine with transmethylation processes. Methyltransfer reactions are impaired in SAHH deficiency. SAHH deficiency is multisystemic and antenatal onset disorder. It is also ultra rare disease. Only 19 cases have been reported so far. Case Presentation: We report an eighteen-month-old female patient who was investigated due to elevated transaminase levels, coagulopathy, cataract, hypotonia, and global developmental delay. She also had dysmorphic findings. Significant methionine elevation and mild homocysteine elevation were detected. Other metabolic investigations and laboratory findings were unremarkable. Homozygous novel variant in the AHCY gene and heterozygous novel variant in the PITX3 gene were found by whole-exome sequencing (WES) analysis. Methionine restricted diet, phosphatidylcholine, and creatine supplements were advised. Conclusion: In this report, a case with a novel variant in the AHCY gene and prominent dysmorphic findings was reported. More SAHH deficiency cases with different findings and phenotypes will be revealed through the use of WES and genetic panels.